scholarly journals Trends in the epidemiology of chronic kidney disease in Russian Federation according to the Federal Diabetes Register (2013–2016)

2018 ◽  
Vol 21 (3) ◽  
pp. 160-169 ◽  
Author(s):  
Minara S. Shamkhalova ◽  
Olga K. Vikulova ◽  
Anna V. Zheleznyakova ◽  
Michail A. Isakov ◽  
Marina V. Shestakova ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Russian Federation ◽  
Stage Renal Disease ◽  
End Stage ◽  
Increasing Trends ◽  
Diabetes Register ◽  
Epidemiological Characteristics

BACKGROUND: Chronic kidney disease (CKD) is one of the most severe complications of diabetes mellitus (DM), this determines the importance of the study of epidemiological characteristics of the disease. AIMS: To assess the epidemiological characteristics of CKD in adult DM patients with type 1 (T1), 2 (T2) in Russian Federation in 201316. METHODS: We have used the database of the Russian Federal Diabetes register, 81st regions included in online register. Indicators were estimated per 10,000 adult DM patients (18years). RESULTS: In 2016, the CKD frequency registration was T1 23%, T2 6.9% with marked interregional differences 1.5-49.9%, 0.623.5%, respectively. The CKD prevalence in dynamics 20132016 was 2171.42303.0 in T1 and 512.687.2 in T2. The incidence of new CKD cases increased 2 times in T1 (215.5 vs 104.2), and 3.7 times in T2 (190.4 vs 51.8). The analysis of distribution by CKD stages by KDIGO indicates the increase in the proportion of patients with low and moderate cardiovascular risk and end stage renal disease (ESRD) (with the initial stages of CKD, C1/2 A1) - 12.046.8% in T1; 10.050.4% in T2. The proportion of patients with a very high risk (stages C4/5 C3aA3 and C3bA2-3) progressively decreases: 13.46.7% in T1, 11.34.4% in T2. We observed relation between the CKD prevalence and DM duration. CKD develops in 5.1% patients if T15 years and in 48.0% if T130years; in T2 3.5% and 20.3%, respectively. The average age of CKD onset in T1 increased for 4,3yr (36,140,2), in T2 for 2,4yr (64,466,8), DM duration until CKD development increased in T1 11.814.2yr, in T2 7.68.2yr. CONCLUSIONS: There is a significant improvement in the quality of CKD diagnostics at the earlier stages, older age and a longer DM duration before CKD onset in both types while we observed the increasing trends in CKD prevalence in Russian Federation in the dynamics of 2013-2016. Advances in the management of patients with DM in recent years do not reduce the risk of CKD, but give us a delay in its development. The marked interregional differences frequency of registration of CKD might indicate some remaining problems in verification in a number of regions where the standard for mandatory assessment of albuminuria and glomerular filtration rate not implemented.

scholarly journals An Update on the Controversies in Anemia Management in Chronic Kidney Disease: Lessons Learned and Lost

Anemia ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Geoffrey Teehan ◽  
Robert L. Benz
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Randomized Trials ◽  
Lessons Learned ◽  
Patients With Diabetes ◽  
Anemia Management ◽  
Erythropoietin Deficiency ◽  
Stage Renal Disease ◽  
End Stage

Background. Erythropoietin deficiency and anemia occur in Chronic Kidney Disease (CKD) and may be treated with Erythropoietin Stimulating Agents (ESAs). The optimal hemoglobin, in non-End Stage Renal Disease CKD, is controversial.Methods. We review three recent randomized trials in anemia in CKD: CHOIR, CREATE, and TREAT.Results. CHOIR (N=1432) was terminated early with more frequent death and cardiovascular outcomes in the higher Hb group (HR 1.34: 95% C.I. 1.03–1.74,P=.03). CREATE (N=603) showed no difference in primary cardiovascular endpoints. Stroke was more common in the higher Hb group (HR 1.92; 95% C.I. 1.38–2.68;P<.001) in TREAT (N=4038).Conclusions. There is no benefit to an Hb outside the 10–12 g/dL range in this population. To avoid transfusions and improve Quality of Life, ESAs should be used cautiously, especially in patients with Diabetes, CKD, risk factors for stroke, and ESA resistance.

scholarly journals Quality of Care in Chronic Kidney Disease and Incidence of End-Stage Renal Disease in Older Patients

Medical Care ◽  
2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Shingo Fukuma ◽  
Tatsuyoshi Ikenoue ◽  
Sayaka Shimizu ◽  
Edward C. Norton ◽  
Rajiv Saran ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Quality Of Care ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Older Patients ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Quality of life predicts risks of end-stage renal disease and mortality in patients with chronic kidney disease

2010 ◽  
Vol 26 (1) ◽  
pp. 392-392
Author(s):  
Y.-C. Tsai ◽  
C.-C. Hung ◽  
S.-J. Hwang ◽  
S.-L. Wang ◽  
S.-M. Hsiao ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Chronic Kidney Disease-Associated Pruritus

Toxins ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 527
Author(s):  
Puneet Agarwal ◽  
Vinita Garg ◽  
Priyanka Karagaiah ◽  
Jacek C. Szepietowski ◽  
Stephan Grabbe ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
End Stage Renal Disease ◽  
English Language ◽  
Advanced Chronic Kidney Disease ◽  
Primary Care Doctors ◽  
Stage Renal Disease ◽  
End Stage ◽  
Distressing Condition

Pruritus is a distressing condition associated with end-stage renal disease (ESRD), advanced chronic kidney disease (CKD), as well as maintenance dialysis and adversely affects the quality of life (QOL) of these patients. It has been reported to range from 20% to as high as 90%. The mechanism of CKD-associated pruritus (CKD-aP) has not been clearly identified, and many theories have been proposed to explain it. Many risk factors have been found to be associated with CKD-aP. The pruritus in CKD presents with diverse clinical features, and there are no set features to diagnose it.The patients with CKD-aP are mainly treated by nephrologists, primary care doctors, and dermatologists. Many treatments have been tried but nothing has been effective. The search of literature included peer-reviewed articles, including clinical trials and scientific reviews. Literature was identified through March 2021, and references of respective articles and only articles published in the English language were included.

Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs

Nephrology ◽  
2010 ◽  
Vol 15 (1) ◽  
pp. 108-115 ◽  
Author(s):  
SHU-YI WEI ◽  
YONG-YUAN CHANG ◽  
LIH-WEN MAU ◽  
MING-YEN LIN ◽  
HERNG-CHIA CHIU ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Care Program ◽  
Medical Costs ◽  
Chronic Kidney Disease Care ◽  
Stage Renal Disease ◽  
End Stage

Advances in Anemia Management in Chronic Kidney Disease

2002 ◽  
Vol 15 (6) ◽  
pp. 437-455 ◽  
Author(s):  
Joanna Q. Hudson ◽  
Kristine S. Schonder
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
The United States ◽  
Left Ventricular ◽  
Negative Consequences ◽  
Secondary Complications ◽  
Anemia Management ◽  
Stage Renal Disease ◽  
End Stage

The prevalence of chronic kidney disease (CKD) is increasing in the United States. Efforts to promote earlier intervention to screen for CKD and manage secondary complications are of paramount importance to improve overall care of this population. Anemia is a secondary complication of CKD that develops as kidney function declines. Historically, anemia management efforts have been primarily emphasized in patients with end-stage renal disease; however, early detection and treatment of anemia in the early stages of the disease are essential to prevent negative consequences of anemia such as reduced quality of life, left ventricular hypertrophy and mortality. With the increased prevalence of CKD and efforts focused on identifying this disorder early in its course, it is likely that more pharmacists will be involved in the management of CKD and secondary complications such as anemia. Treatment approaches must also be based on the more recently advocated guidelines from the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI). This article reviews therapeutic issues of anemia of CKD, new agents for management, and the NKF-K/DOQI anemia management guidelines from a clinical perspective that will assist pharmacists involved in the care of these patients.

scholarly journals Quality of life predicts risks of end-stage renal disease and mortality in patients with chronic kidney disease

2009 ◽  
Vol 25 (5) ◽  
pp. 1621-1626 ◽  
Author(s):  
Y. C. Tsai ◽  
C. C. Hung ◽  
S. J. Hwang ◽  
S. L. Wang ◽  
S. M. Hsiao ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Role of Myeloperoxidase in Patients with Chronic Kidney Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Bojana Kisic ◽  
Dijana Miric ◽  
Ilija Dragojevic ◽  
Julijana Rasic ◽  
Ljiljana Popovic
Keyword(s):  
Oxidative Stress ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Public Health Problem ◽  
Cardiovascular Complications ◽  
The Body ◽  
Stage Renal Disease ◽  
End Stage

Chronic kidney disease (CKD) is a worldwide public health problem. Patients with CKD have a number of disorders in the organism, and the presence of oxidative stress and systemic inflammation in these patients is the subject of numerous studies. Chronic inflammation joined with oxidative stress contributes to the development of numerous complications: accelerated atherosclerosis process and cardiovascular disease, emergence of Type 2 diabetes mellitus, development of malnutrition, anaemia, hyperparathyroidism, and so forth, affecting the prognosis and quality of life of patients with CKD. In this review we presented the potential role of the myeloperoxidase enzyme in the production of reactive/chlorinating intermediates and their role in oxidative damage to biomolecules in the body of patients with chronic kidney disease and end-stage renal disease. In addition, we discussed the role of modified lipoprotein particles under the influence of prooxidant MPO intermediates in the development of endothelial changes and cardiovascular complications in renal failure.

Sign in / Sign up

Export Citation Format

Share Document